Copied
 
 
Formål
Formål
Selskabets formål er at være biotekselskab, investering samt enhver beslægtet virksomhed efter ledelsens beslutning.
Sidst opdateret den 26.08.2019 og angivet som gældende fra 26.08.2019 (1827 dage).
Ingen historik.
Status
Virksomhedsstatus
NORMAL.
Sidst opdateret den 26.08.2019 og angivet som gældende fra 26.08.2019 (1827 dage).
Ingen historik.
Branche
Branche
Fremstilling af farmaceutiske præparater (212000).
Sidst opdateret den 26.08.2019 og angivet som gældende fra 26.08.2019 (1827 dage).
Ingen historik.
Revision
Revisionfravalgt
true.
Sidst opdateret den 26.08.2019 og angivet som gældende fra 26.08.2019 (1827 dage).
Ingen historik.
Revisor
Ingen nuværende registrering.
Ingen historik.
Form
Virksomhedsform
80.
Sidst opdateret den 26.08.2019 og angivet som gældende fra 26.08.2019 (1827 dage).
Ingen historik.
Kontakt
Kontaktoplysninger
contact@tetrapharm.eu.
Sidst opdateret den 26.02.2020 og angivet som gældende fra 26.02.2020 (1643 dage).
HistorikStartStop
contact@tetrapharm.eu26.02.2020
martinsrose@yahoo.com26.08.201925.02.2020
Telefon
Ingen nuværende registrering.
Ingen historik.
Navne
Ingen historik.
Binavne
Binavne
TPT ApS.
Sidst opdateret den 26.08.2019 og angivet som gældende fra 26.08.2019 (1827 dage).
Ingen historik.
Tegningsregel
Tegningsregel
Selskabet tegnes af en direktør sammen med bestyrelsesformanden eller af den samlede bestyrelse i forening.
Sidst opdateret den 06.09.2021 og angivet som gældende fra 03.09.2021 (1088 dage).
Fortolkning (2 tegningsmuligheder)
1 direktør + formanden
bestyrelsen
HistorikStartStop
Selskabet tegnes af en direktør sammen med bestyrelsesformanden eller af den samlede bestyrelse i forening03.09.2021
Selskabet tegnes af en direktør26.08.201902.09.2021
Ansatte
26.08.2024
Ingen historik.
Kapital
26.08.2024
Fra årsrapport
Type af revisorbistand:Revisionspåtegning
Navn på revisionsvirksomhed:EY Godkendt Revisionspartnerselskab
Revisionsvirksomhedens CVR-nr.:30700228
Beskrivelse af revisor:State Authorised Public Accountant
Virksomhedens regnskabsklasse:Regnskabsklasse B
Grundlag for konklusion (revision):We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. Independence We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code.
Konklusion (revision):We have audited the financial statements of Tetra Pharm Technologies ApS for the financial year 1 January - 31 December 2023, which comprise income statement, balance sheet, statement of changes in equity and notes, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act. In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2023 and of the results of the Company's operations for the financial year 1 January - 31 December 2023 in accordance with the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Management is responsible for the Management's review. Our opinion on the financial statements døs not cover the Management's review, and we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated. Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act. Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of the Management's review.
Bibranche
Ingen nuværende registrering.
Ingen historik.
Børsnoteret
26.08.2024
Ingen nuværende registrering.
Ingen historik.
Hjemmeside
26.08.2024
Ingen nuværende registrering.
Ingen historik.